Global Payments Inc vs Immunovant Inc. Common Stock — how do they compare? Global Payments Inc trades at $82.81 (market cap $21.46B), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Global Payments Inc is far larger — about 3.2× Immunovant Inc. Common Stock's market cap, and Global Payments Inc pays a 1.23% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Immunovant Inc. Common Stock for 0 Days on average.
| GPN | IMVT | |
|---|---|---|
Market Cap | $21.46B | $6.62B |
Volume | 1,482,600 | 1,131,364 |
Sector | Financials | Health |
52-Week High | $94.83 | $44.96 |
52-Week Low | $62.47 | $17.03 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $39.60B | $5.72B |
Dividend Yield | 1.23% | — |
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.77, up 1.2% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with strong gross margins (63.91%) but negative net income margin (-9.15%) and ROE (-4.09%). Recent news highlights Genius platform growth and Worldpay integration driving momentum, though rising costs and debt remain concerns. Cash flow trends show volatility with 2025 net cash flow of $6.38B but projected decline to $2.4B in 2026.
Analyst consensus remains bullish with 59% buy ratings and $102.75 price target, suggesting 24% upside. Key opportunities include digital payment expansion and margin improvements, while risks involve debt levels (debt-to-asset ratio 41.57% in 2025) and competitive pressures. The stock trades below book value (P/B 0.93) but at elevated P/E (38.43), requiring execution on growth initiatives to justify valuation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →